EULAR POINTS TO CONSIDER/RECOMMENDATIONS
ADHERENCE TO BIOLOGICAL THERAPY IN CHRONIC OSTEOPOROTIC FRACTURES.

...recommendations using second Delphi round; vi) a field test.

Conclusions: The immediate effects of neck stabilisation exercises on proprioceptive function of neck may reflect that these exercises, may enhance postural awareness and control while in motion.

REFERENCES:

Disclosure of Interest: None declared

THU0726-HPR
EULAR POINTS TO CONSIDER/RECOMMENDATIONS FOR THE HEALTH PROFESSIONALS’ PREVENTION AND MANAGEMENT OF OSTEOPOROTIC FRACTURES

E. Hurkmans1, N. Wilson2, T. Stamm3, J. Adams2, on behalf of Task force group

Background: Interventions delivered by non-physician health professionals, such as physiotherapists, occupational therapists and nurses play an important role in effective management of patients with osteoarthritis or osteoporosis.

Objectives: To establish EULAR Points to Consider/Recommendations for the prevention and management of osteoporotic fractures by non-physician health professionals.

Methods: Points to consider/recommendations were developed according to EULAR standard procedures1 using six stages: i) establishment of an international expert panel/task force including patients, rheumatologists, orthopaedic surgeons and health professionals; ii) a first Delphi-round to set up clinical questions; iii) a literature review; iv) a task force meeting to review the results of the literature search and to formulate points to consider/recommendations; v) development of consensus and assessment of the level of agreement with the points to consider/recommendations using second Delphi round; vi) a field test.

Results: Eight clinical questions and two overarching principles were formulated, subject to the literature search (the clinical questions only) and discussed and refined during the task force meeting. The two overarching principles focused on the importance of shared decision making between patients and professionals and the involvement of different health professionals. Two clinical questions were merged and the task force finally agreed on seven recommendations/points to consider: 1) Health professionals should start with fall risk evaluation in patients at risk of primary or secondary fracture. Patients with high risk should be evaluated by a health professional using multi-component screening, or referred to another health professional competent in multi-component screening. 2) Health professionals should start with fall risk evaluation in patients at high risk of primary osteoporotic fracture and/or high risk of falls. 3) Health professionals should be offered opportunities for adequate treatment, and address bone fragility through patient education.

Conclusions: These points to consider/recommendations should be applied by health professionals in the prevention and management of osteoporotic fracture to ensure high quality care.

REFERENCE:

Disclosure of Interest: None declared

THU0725-HPR
ADHERENCE TO BIOLOGICAL THERAPY IN CHRONIC INFLAMMATORY RHEUMATISM: RESULTS OF A RETROSPECTIVE STUDY IN AUVERGNE, FRANCE

F. Fayet, M.R. Rodere, C. Savel, B. Pereira, M. Soubrier, M. Couedic. Hospital Gabriel Montpied, Clermont-Ferrand, France

Background: The arsenal of treatment options for Chronic inflammatory rheumatism (CIR) has considerably grown over recent years with the biological therapies. Patient adherence to treatment is a major barrier to proper disease management. Patient education enhances drug adherence by improving the knowledge and skills needed to manage the disease and treatments.

Objectives: This study aimed to assess adherence to subcutaneous biological therapy using the Morisky Medication Adherence Scales (MMAS-4) in patients with CIR: rheumatoid arthritis (RA), ankylosing spondylitis (SA) and psoriatic arthritis (PsA), who received education in our department.

Methods: This was a retrospective single-centre observational study of routine care. All patients on subcutaneous biological therapy who received at least one education interview between 2009 and 2013 were included. Adherence was assessed using the Morisky questionnaire (MMAS-4). A comparison of adherence was made based on the BIOSECURE questionnaire (knowledge and skills relating to biological therapy) and type of educational model received by patient (model 1: providing information; model 2: performing one-on-one education; model 3: performing head to head and group-based education). Adherence was also compared based on population characteristics, type of care (mixed or solely hospital), type of CIR, number of education interviews, injection frequency and type of biological therapy.

Results: A total of 193 patients were included in the study, 124 of whom were women. The population’s mean age was 53.3±14.8 years. Patients had had CIR for 10 years, 5–14 with 113 patients suffering from RA, 73 from SA, and 7 from PsA. Of the 193 patients, 192 (99.5%) were on TNF inhibitors (of whom 107 [55.4%] were on etanercept, 58 [30.1%] on adalimumab, 10 [5.2%] on certolizumab and 17 [8.8%] on golimumab) while 1 (0.5%) was on abatacept. About 75.7% (n=146) were on etanercept, 58 [30.1%] on adalimumab, 10 [5.2%] on certolizumab and 17 [8.8%] on golimumab while 1 (0.5%) was on abatacept. About 75.7% (n=146) of the patients reported good adherence (Morisky=0), 17.6% (n=34) moderate adherence (Morisky=1 or 2), and 6.7% (n=13) poor adherence. No significant association was observed between adherence and type of biological therapy.

Conclusions: A comparison of adherence was made based on the BIOSECURE questionnaire (knowledge and skills relating to biological therapy) and type of educational model received by patient (model 1: providing information; model 2: performing one-on-one education; model 3: performing head to head and group-based education). Adherence was also compared based on population characteristics, type of care (mixed or solely hospital), type of CIR, number of education interviews, injection frequency and type of biological therapy.

Disclosure of Interest: None declared